Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease

Annals of Neurology

Volumn 74, Issue 5, 2013, Pages 655-668

  Podlesniy, Petar ^a,b   Figueiro Silva, Joana ^a,b   Llado, Albert ^c,d   Antonell, Anna ^c,d   Sanchez Valle, Raquel ^c,d   Alcolea, Daniel ^b,e   Lleo, Alberto ^b,e   Molinuevo, Jose Luis ^c,d   Serra, Nuria ^a,b   Trullas, Ramon ^a,b,d  

^a INST D INVESTIGACIONS B   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; MITOCHONDRIAL DNA; PRESENILIN 1; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL CULTURE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DEMENTIA; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE DOSAGE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84890797694     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23955     Document Type: Article

References (24)

1. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
2. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
3. Clark CM, Xie S, Chittams J, et al. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003; 60: 1696-1702.
4. Hertze J, Minthon L, Zetterberg H, et al. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis 2010; 21: 1119-1128.
5. Strozyk D, Blennow K, White LR, et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003; 60: 652-656.
6. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006; 59: 512-519.
7. Tapiola T, Alafuzoff I, Herukka SK, et al. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009; 66: 382-389.
8. Galvin JE, Powlishta KK, Wilkins K, et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol 2005; 62: 758-765.
9. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837-1844.
10. Mattsson N,. CSF biomarkers in neurodegenerative diseases. Clin Chem Lab Med 2011; 49: 345-352.
11. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010; 330: 1774.
12. Bian H, Van Swieten JC, Leight S, et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 2008; 70: 1827-1835.
13. Swerdlow RH, Burns JM, Khan SM,. The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 2010; 20 (suppl 2): S265-S279.
14. Coskun P, Wyrembak J, Schriner S, et al. A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta 2012; 1820: 553-564.
15. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
16. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-622.
17. Hunter SE, Jung D, Di Giulio RT, et al. The QPCR assay for analysis of mitochondrial DNA damage, repair, and relative copy number. Methods 2010; 51: 444-451.
18. Guo W, Jiang L, Bhasin S, et al. DNA extraction procedures meaningfully influence qPCR-based mtDNA copy number determination. Mitochondrion 2009; 9: 261-265.
19. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546-1554.
20. Coskun PE, Wyrembak J, Derbereva O, et al. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and Down syndrome dementia. J Alzheimers Dis 2010; 20 (suppl 2): S293-S310.
21. Sheng B, Wang X, Su B, et al. Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease. J Neurochem 2012; 120: 419-429.
22. Area-Gomez E, de Groof AJ, Boldogh I, et al. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. Am J Pathol 2009; 175: 1810-1816.
23. Pavlov PF, Wiehager B, Sakai J, et al. Mitochondrial gamma-secretase participates in the metabolism of mitochondria-associated amyloid precursor protein. FASEB J 2011; 25: 78-88.
24. Wallace DC,. Bioenergetic origins of complexity and disease. Cold Spring Harb Symp Quant Biol 2011; 76: 1-16.